AAV Hybrid Serotypes: Improved Vectors for Gene Delivery by Choi, Vivian et al.
AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Vivian W. Choi1,2, Douglas M. McCarty3, and R. Jude Samulski1,2,*
1 Department of Pharmacology and
2 Gene Therapy Center, University of North Carolina at Chapel Hill. Chapel Hill. NC 27599, USA,
3 Columbus Children’s Research Institute, Center for Gene Therapy, Columbus Children’s Hospital,
and Department of Pediatrics, College of Medicine and Public Health, The Ohio State University,
Columbus, Ohio 43205, USA.
Abstract
In recent years, significant efforts have been made on studying and engineering adeno-associated
virus (AAV) capsid, in order to increase efficiency in targeting specific cell types that are non-
permissive to wild type (wt) viruses and to improve efficacy in infecting only the cell type of interest.
With our previous knowledge of the viral properties of the naturally occurring serotypes and the
elucidation of their capsid structures, we can now generate capsid mutants, or hybrid serotypes, by
various methods and strategies. In this review, we summarize the studies performed on AAV
retargeting, and categorize the available hybrid serotypes to date, based on the type of modification:
1) transcapsidation, 2) adsorption of bi-specific antibody to capsid surface, 3) mosaic capsid, and 4)
chimeric capsid. Not only these hybrid serotypes could achieve high efficiency of gene delivery to
a specific targeted cell type, which can be better-tailored for a particular clinical application, but also
serve as a tool for studying AAV biology such as receptor binding, trafficking and genome delivery
into the nucleus.
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ABBREVIATIONS
AAV = Adeno-associated virus; Ad = Adeno Virus; αvβ5 = Integrin alpha-V-beta-5; Cap = Capsid
protein; FGFR1 = Fibroblast growth factor receptor - 1; GAG = Glycosaminoglycan; GFP = Green
fluorescent protein; HGFR = Hepatocyte growth factor receptor; HSPG = Heparan sulfate
proteoglycans; HSV = Herpes simplex virus; ITR = Inverted terminal repeat; RBS = Rep binding
site; Rep = Replication protein; scAAV = Self-complementary adeno-associated virus; SV = Simian
adeno virus; TRS = Terminal resolution site; VP = Viral proteins; WT = Wild-type
INTRODUCTION
Adeno-Associated Virus (AAV) is a non-pathogenic single-stranded DNA parvovirus, with a
capsid diameter of 26nm. Each end of the single-stranded DNA genome contains an inverted
terminal repeat (ITR), which is the only cis-acting element required for genome replication
and packaging. The genome carries two viral genes: rep and cap. The virus utilizes two
promoters and alternative splicing to generate four proteins necessary for replication (Rep78,
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Rep 68, Rep 52 and Rep 40), while a third promoter generates the transcript for three structural
viral capsid proteins, 1, 2 and 3 (VP1, VP2 and VP3), through a combination of alternate
splicing and alternate translation start condons [Berns, KI and Linden, RM, 1995]. The three
capsid proteins share the same C-terminal 533 amino acids, while VP2 and VP1 contain
additional N-terminal sequences of 65 and 202 amino acids, respectively. The AAV virion
contains a total of 60 copies of VP1, VP2, and VP3 at a 1:1:20 ratio, arranged in a T=1
icosahedral symmetry [Rose, JA et al., 1971; Muzyczka, N. 1992].
As a dependovirus, AAV requires Adenovirus (Ad) or Herpes Simplex Virus (HSV) as a helper
virus to complete its lytic life-cycle [Atchison, RW et al., 1965; Hoggan, MD et al., 1966;
Conway, JE et al., 1997], In the absence of the helper virus, wt AAV establishes latency by
integration with the assistance of Rep proteins through the interaction of the ITR with the
chromosome [Berns, KI and Linden, RM, 1995]. Recombinant AAV (rAAV) gene delivery
vectors can be produced by removing the two viral genes (rep and cap) and inserting a transgene
expression cassette between the two ITRs, with Rep and Cap provided in trans. Because there
are no viral genes in the rAAV, toxicity associated with this vector is minimal. Therefore,
rAAV vectors are a desirable tool used in delivering a vast range of transgenes applicable to
many disease models.
For a gene delivery vector, a successful therapeutic outcome can only be achieved by efficient
infection of target tissues and establishment of long term gene expression. It has been
extensively demonstrated that rAAV can successfully infect and transduce a broad variety of
cell and tissue types, such as brain, liver, muscle, etc [During, MJ et al., 1998; Song, S et al.,
1998; Ye, X et al., 1999; Acland, GM et al., 2001; Flotte, TR, 2001] and has the ability to
infect both dividing and quiescent cells [Lewis, PF and Emerman, M. 1994; Alexander, IE et
al., 1996]. Not only can rAAV infect a broad spectrum of cell types, long term gene expression
greater than 1.5 years has also been demonstrated in animal models including canine, murine
and hamster [McCown, TJ et al., 1996; Xiao, X et al., 1996; Monahan, PE et al., 1998; Herzog,
RW et al., 1999; Snyder, RO et al., 1999; Cottard, V et al., 2000; Song, S et al., 2001; Asfour,
B et al., 2002; Li. J et al., 2003].
At the cellular level, AAV undergoes 5 major steps prior to achieving gene expression: 1)
binding or attachment to cellular surface receptors, 2) endocytosis, 3) trafficking to the nucleus,
4) uncoating of the virus to release the genome and 5) conversion of the genome from single-
stranded to double-stranded DNA as a template for transcription in the nucleus. The cumulative
efficiency with which rAAV can successfully execute each individual step, determines the
overall transduction efficiency. Rate limiting steps in rAAV transduction include the absence
or low abundance of required cellular surface receptors for viral attachment and internalization,
inefficient endosomal escape leading to lysosomal degradation, and slow conversion of single-
stranded to double-stranded DNA template. Therefore, with a better understanding of AAV
biology, vectors with modifications to the genome and/or the capsids can be designed to
facilitate more efficient or more specific transduction or cells or tissues for gene therapy.
In this review, we will focus our discussion on the ongoing efforts made in 1) understanding
the naturally existing AAV serotypes (1–11); 2) the importance of AAV crystal structure and
its applications; and 3) methods and strategies for generating hybrid serotypes with capsid
protein modifications that increase the efficiency and efficacy of viral infection in tissues of
interest, including i) transcapsidation, ii) adsorption of antibody to capsid surface, iii) mosaic
capsid, and iv) chimeric capsid. Also, we will discuss the implications of these AAV hybrid
serotypes for gene therapy as well as AAV biology, including signal transduction, trafficking,
and virion assembly. Important intricacies of using these hybrid serotypes will also be
discussed.
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Before discussing the development of novel rAAV hybrid vectors, it is important to define
AAV serology, because there has been controversy in the field regarding what constitutes a
new serotype. Serology is defined as the inability of an antibody that is reactive to the viral
capsid proteins of one serotype in neutralizing those of another serotype. As more and more
naturally occurring isolates of AAV are discovered and AAV capsid mutants generated, the
true distinctions between serotypes can become blurred. Theoretically, a new serotype can only
be named when the newly isolated virus of interest has been tested for neutralization against
serum specific for all existing and characterized serotypes. If there is no serological difference
with any of the currently existing serotypes, then the new virus is a subgroup or variant of the
corresponding serotype. Therefore, naturally occurring serotypes discussed in this review are
under the working definition of serotype as discussed in published studies and mutant viruses
with modifications are considered as hybrid serotypes. In most cases, serology testing has yet
to be performed on mutant viruses with capsid sequence modifications.
1.1. Isolation of AAV Serotypes from Animal Tissues: AAV1 - 11
AAV serotype 2 (AAV2) was the first AAV serotype to be cloned into bacterial plasmids
[Samulski, RJ et al., 1982] after its discovery as a contaminant in an Adenovirus type 12 stock
[Hoggan, MD et al., 1966], A tremendous amount of work has been performed on
understanding the biology of AAV2, and therefore it is the best characterized among all
naturally discovered serotypes. As a consequence, early AAV clinical trails have been heavily
focused on the use of AAV2. Since the discovery of AAV2, 10 other serotypes have been
discovered and cloned for development into gene therapy vectors.
AAV1 and AAV3 were found to be contaminants of a simian Adenovirus type 15 (SV15) stock
[Atchison, RW et al., 1965] and Adenovirus type 7 [Hoggan, MD et al., 1966], respectively.
AAV3 has an overall sequence similarity of 82% with AAV2 [Muramatsu, S et al., 1996]. A
genetic variant, AAV3B, with differences in only 16 nucleotides was also identified in the
stock from which AAV3 was isolated. AAV4 particles, and their corresponding antibodies,
were isolated only in African green monkeys infected with SV15 stock [Parks, WP et al.,
1967] and were subsequently cloned and used as a vector by Chiorini and co-workers [Chiorini,
JA et al., 1997]. Interestingly, its genome has been demonstrated to integrate preferentially
into simian chromosomes in CV-1 cells [Amiss, TJ et al., 2003]. AAV5, originally identified
from a human clinical sample [Bantel-Schaal, U and zur Hausen, H, 1984; Rutledge, EA et
al., 1998], contains ITRs that are structurally similar to AAV2, but are only 58% identical at
the sequence level [Chiorini, JA et al., 1999], The rep-binding site (RBS) in the AAV5 ITR is
conserved between AAV5 and AAV2, but the terminal resolution site (trs) for Rep mediated
DNA endonuclease activity is different. The AAV5 RBS is larger and the spacing between the
trs and the RBS is greater than AAV2. The nucleotide sequence of AAV5 rep is 67% identical
to AAV2 Rep, while the sequence of AAV5 cap is only 56% identical to AAV2 cap. AAV5
is one of the most divergent of the AAV serotypes [Chiorini, JA et al., 1999]. AAV6 was
isolated as a contaminant of an adenovirus type 5 stock and is believed to be either a variant
of AAV1, with only 6 amino acids difference between their capsids [Rutledge, EA et al.,
1998], or a natural recombinant between AAV1 and AAV2 [Xiao, W et al., 1999]. AAV7 and
AAV8 were isolated from rhesus monkey tissues [Gao, GP et al., 2002] by PCR, utilizing
primers to highly conserved regions of the capsid sequence, AAV9, which was isolated from
human tissue, demonstrated high transduction efficiency in the lung, muscle and liver [Gao,
G et al., 2004]. AAV10 and AAV11 were isolated from cynomolgus monkey tissue using a
similar PCR strategy, and demonstrated the ability to infect both human and monkey cells
[Mori, S et al., 2004]. In addition to human and primates, AAV has also been isolated from
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different species including cow [Schmidt, M et al., 2004], chicken [Bossis. I and Chiorini, JA,
2003], sheep [Clarke, JK et al., 1979], snake [Farkas, SL et al., 2004], lizard [Jacobson, ER
et al., 1996], and goat [Olson, EJ et al., 2004]. The isolation of new AAV serotypes from animal
tissues and the development of these new variants into gene therapy vectors are discussed in
a separate review in this issue [Gao et al.].
1.2. The Best Characterized AAV Serotype: AAV2
Among all naturally occurring serotypes isolated to date, AAV2 is the best characterized and
extensively studied and has served as the archetype for AAV biology. The first step of AAV
infection is to utilize cell surface receptor as the initial step in docking and interacting with cell
surface moieties. Different AAV serotypes are infectious in different cell types, depending on
the availability of suitable high-affinity receptor molecules. Heparan sulfate proteoglycan
(HSPG), a widely-expressed cell surface receptor, is the only type of glycosaminoglycan
(GAG) that AAV2 uses as a primary receptor for cell attachment, and the efficiency of AAV
infection is directly related to the presence and concentration of HSPG receptors [Summerford,
C and Samulski, RJ, 1998]. AAV2 also utilizes co-receptors to assist its internalization,
including the fibroblast growth factor receptor-1 (FGFRI) [Qing, K et al., 1999], integrin alpha-
V-beta-5 (αvβ5) [Summerford, C et al., 1999], and hepatocyte growth factor receptor (HGFR)
[Kashiwakura, Y et al., 2005]. Qing and co-workers suggested that AAV infection is more
efficient when HSPG and FGFR are co-expressed on the cell surface, as HSPG serves as the
initial docking receptor for AAV2 and FGFR assists viral internalization into the cell. [Qing,
K et al., 1998]. While the cellular receptors for some AAV serotypes are still unknown,
significant progress has been made in our understanding of the interaction between cellular
surface receptors and other AAV serotypes. It has been demonstrated that AAV4 binds to O-
linked α2–3 linked sialic acid, while AAV5 binds to N-linked α2–3 or 2–6 sialic acid [Kaludov,
N et al., 2001; Walters, RW et al., 2001], A co-receptor, platelet-derived growth factor receptor
(PDGFR-α), has also been identified for AAV5 [Di Pasquale, G et al., 2003].
Following receptor binding, rAAV2 particles enter the cell via a dynamin-dependent clathrin-
coated pit endocytosis pathway. The virus is then trafficked from early endosome to late
endosome, and is believed to escape from the endosome and accumulate in a perinuclear pattern
before the genome is delivered to the nucleus [Weitzman, MD et al., 1996; Duan, D et al.,
1999; Bartlett, JS et al, 2000; Hansen, J et al., 2000; Sanlioglu, S et al., 2000; Xiao, W et
al., 2002]. With the assistance of host cell DNA polymerase, the genome is converted from
single-stranded to double-stranded DNA, which serves as a transcription template. While the
full scope of differences between the known wt serotypes, and their relationship to the
establishment of successful transduction is yet to be fully investigated, it is already recognized
that these differences can be exploited and expanded upon to achieve the desired target cell
specificity for gene therapy applications. These efforts have been greatly aided, in terms of
effective modification of the features that give rise to the different serotypes, through a detailed
knowledge of the AAV capsid structure and the spatial distribution of these features.
1.3. Capsid Crystal Structure: So Much to Learn
The viral capsid protein is the first element that cellular receptor encounters during a viral
infection. In order to rationally design vectors for a particular target, it is important for us to
know the structure of the viral capsid and its surface topology and understand the interactions
between each AAV serotype and its corresponding cellular receptor. X-ray crystallography is
a powerful tool to study the structure of proteins, and advances in this technology have
dramatically increased the number of viral capsid proteins that have been characterized in
recent years. Not only can the existing conformation of capsid proteins be analyzed by this
technique, but also the computational methods used to visualize these structures can facilitate
in silico prediction of the structures of various mutant capsids.
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The first few parvovirus capsid structures to be solved were the canine parvovirus [Tsao, J et
al., 1991], followed by feline panleukopenia virus [Agbandje, M et al., 1993], B19 [Chipman,
PR et al., 1996; Kaufmann, B et al., 2004], the minute virus of mice (MVM) [Llamas-Saiz,
AL, 1997] and Galleria mellonella densovirus [Simpson, AA et al., 1998]. The structural details
from these parvovirus capsids have been used as a foundation for many AAV studies because
of their structural similarity in several domains. A hypothetical AAV surface model was
developed by comparing the canine parvovirus VP2 to the AAV VP3 proteins [Girod, A et
al., 1999], which served as a guide for designing capsid modifications which could alter cell
tropism. However, because canine parvovirus binds to different types of cell surface molecules,
knowledge of the exact AAV2 capsid topology is critical in fully understanding how the virus
interacts with its cellular surface receptor. The structure of AAV2 was eventually determined
at a resolution of 3-Å by X-ray crystallography in 2002 [Xie, Q et al., 2002]. The crystal
structure resolved the VP3 capsid subunit, except for the 14 ammo acids near its N-terminus,
and the unique residues of the N-terminus of VP1 and VP2 (amino acids 1-202). The β-barrel
core structure of the AAV capsid is a common feature among other parvoviruses, but the long
loops between the β-strands contribute to the formation of the 3-fold proximal peaks, giving a
unique surface topology to AAV2. Structural analysis of AAV2 and its primary cellular
receptor HSPG revealed that the 3-fold peaks, which are composed of loops contributed from
three different capsid subunits, are responsible for its binding. In light of this information,
capsid modifications in previous studies [Bartlett, JS et al., 1999; Girod, A et al., 1999;
Rabinowitz, JE et al., 1999; Wu, P et al., 2000] can now be re-examined in terms of the interplay
between their overall structure and the corresponding functionality.
Structural analysis of other AAV serotypes suggests that their capsid surface topology differs,
which may account for their unique tropism. For example, Walters et al. determined the
structure of AAV5 at a resolution of 16-Å, and demonstrated that the spikes on the three-fold
axis of AAV2 are larger and more pointed than the mounds on AAV5 on the same axis [Walters,
RW et al., 2004]. Surprisingly, no specific domain on the AAV5 capsid has been identified to
be responsible for sialic acid binding. Because the preliminary crystal structure of AAV4 has
been determined at a resolution of 3.2-Å [Kaludov, N et al., 2003], it is possible that
comparisons of the AAV4 and AAV5 structures could provide useful hints to determine the
domain responsible for cellular receptor specificity. With the availability of the AAV crystal
structure, the design of the mutant virus is much more systematic, highlighting the importance
of visualization of the surface topology in creating better binding to target receptors.
The structural data for AAV could only be achieved through the generation of pure crystals,
which required improvement in AAV purification methods [Xie, Q et al., 2004]. The large
scale AAV2 production was accomplished through adaptation of producer cells to suspension
culture and re-optimization of the times of infection and transfection, yielding highly
concentrated AAV (1015 particles/ml) at 99% purity for crystallization. While affinity column
purification is feasible for AAV2, using a heparin column [Summerford, C and Samulski, RJ,
1999], and AAV5 using a mucin column [Auricchio, A et al., 2001], other serotypes could not
be purified in the same fashion, and rely on CsCl density fractionation. Recent developments
in AAV purification mostly utilize ion exchange column purification. Kaludov et al. (2002)
described a two step purification utilizing an anion-exchange column and high molecular
weight retention filters [Kaludov, N et al., 2002]. This method is suitable for all serotypes
without using affinity chromatography, which requires knowledge of the cellular receptor, and
serves as an alternative protocol to CsCl density gradients. These advancements in purification
can potentially accelerate the process of purifying high quality crystals for structural analysis
of other AAV serotypes.
The following sections describe AAV capsid studies conducted both before and after the crystal
structure of AAV2 were available. With the structure known, the exact position of an epitope
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to be tagged or a mutation to be made can be studied in silico before performing the biological
studies, thus providing a more rational design of capsid modification.
2. AAV HYBRID SEROTYPES
Since the development of naturally occurring AAV serotypes into gene therapy vectors,
researchers have spent much effort in understanding the tropism of each serotype so that further
modification to the virus could be performed to enhance the efficiency of gene transfer. These
efforts also encompassed the idea of swapping domains from one serotype capsid to another,
to create hybrid vectors with desirable qualities from each parent. As the viral capsid is
responsible for cellular receptor binding, the understanding of viral capsid domain(s) critical
for binding is important. Mutation studies on the viral capsid (mainly on AAV2) performed
before the availability of the crystal structure were mostly based on capsid surface
functionalization by adsorption of exogenous moieties, insertion of peptide at a random
position, or comprehensive mutagenesis at the amino acid level. In this review, we would like
to discuss the properties of various types of AAV hybrid serotypes according to the following
categories:
2.1 Transcapsidation - Packaging the genome containing ITRs from one serotype in the capsid
of a different serotype;
2.2 Adsorption modification - Carries foreign peptides adsorbed on the capsid surface;
2.3 Mosaic Capsid - Packaging a mixture of unmodified capsid proteins from two different
serotypes;
2.4 Chimeric Capsid - Packaging capsid proteins with foreign peptide sequence fused at either
the N- or C-terminus of viral protein or, as an insertion into the VP sequence.
2.1. Transcapsidation – ITR from One Serotype Cross-Packaged into Capsid of a Different
Serotype
AAV transcapsidation is to package an AAV genome containing an ITR from one serotype
into the capsid of another serotype. Because AAV2 is the most studied serotype, and served
as the archetype for AAV replication research, its genetic and biochemical properties, and the
host cell response to the AAV2 ITR, is the best understood. In addition, most of the vectors
used in previous studies were built with the AAV2 ITR, therefore it is logical to choose the
AAV2 ITR to be cross-packaged into different serotype capsids, in order to expand the use of
the vector for better targeting of cell types that do not express the receptors that AAV2 utilizes.
Several groups first cross-packaged AAV2 ITR into other serotype capsids by complementing
with the homologous Rep proteins for either the ITR or the capsid. Davidson et al (2000) cross-
packaged AAV2 ITR into AAV4 capsid and compared the transduction efficiency of this virus
in the central nervous system to AAV5 vector containing a genome with AAV5 ITR [Davidson,
BL et al., 2000]. However, the transduction efficiency of the above two vectors cannot be
directly compared because the genome was flanked by ITRs from two different serotypes, and
these may influence gene expression independently of the behavior of the capsid. A better
strategy is to package the same serotype ITR into the capsids of all serotypes to be studied. In
two other studies, an AAV2 ITR genome was cross-packaged into AAV 1, 2 and 5, respectively,
for investigating muscle [Hildinger, M et al., 2001] and retina [Auricchio, A et al., 2001]
tropism. In these studies, the transduction efficiency from different serotype capsids can be
evaluated in the absence of potential effects from the expression or stability of the genome.
However, all of the cross packaging viruses were prepared by providing cells with Rep from
AAV2 (Rep2) only. A drawback of this strategy is that the transencapsidated AAV2 ITR into
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AAV5 capsid vector suffered from low titer yield, because the trs of AAV5 is significantly
different from the trs of AAV1, 2, 3, 4 and 6, and Rep2 cannot efficiently nick or process the
AAV5 ITR trs [Chiorini, JA et al., 1999]. A further complication is that while the N-terminus
of Rep mediates specific ITR binding, the C-terminus appears to interact specifically with the
capsid [Dubielzig, R et al., 1999]. Therefore, an alternative strategy is required for generating
higher titer cross-packaged virus. A more comprehensive study was performed to cross-
package AAV2 ITR-containing genomes into the capsids of AAV1, 2, 3, 4 and 5 by engineering
chimeric rep fusion proteins from AAV2 and the Rep proteins specific for each serotype
[Rabinowitz, JE et al., 2002]. The efficiency of interaction between the hybrid Reps and the
serotype-specific capsids is increased, producing titers of cross-packaged vectors similar to
that of AAV2.
2.2. Adsorption of Receptor Ligands to AAV Capsid Surface
Even though there are 11 (to date) identified AAV serotypes that can transduce different tissues
efficiently, there are still specific cell types that are non-permissive to any of these serotypes
and therefore, AAV transcapsidation cannot improve the transduction of those cell types. In
order to take advantage of the attractive properties of AAV vectors for therapeutic purposes,
including long-term gene expression with minimal toxicity, capsid modification studies on
AAV were performed with the aim of retargeting the virus to infect new cell types of interest.
One of the many approaches was to use an AAV-specific antibody that is chemically linked
to another antibody that binds specifically to a cellular receptor known to be highly expressed
on the targeted cell type. This is one of the first approaches in altering AAV capsid tropism
without extensive knowledge of capsid structures. AAV2 was modified with a bi-spectfic F
(ab′ gamma)2 antibody, using monoclonal A20 antibody recognizing AAV2 capsid [Wistuba,
A et al., 1995], and chemically crosslinked to Fab′ arms of the α11β3 integrin binding
monoclonal AP-2 antibody [Bartlett, JS et al., 1999]. This vector was shown to display altered
tropism to target α11β3 integrin expressing DAMI and MO7e megakaryocyte cells
[Ponnazhagan, S et al., 1996] instead of HSPG expressing cells. This study is considered to
be one of the first milestones in the effort to retarget AAV to non-permissive cell types. Another
study that utilized ligand-adsorption on the viral surface for re-targeting was performed by
Ponnazhagan and co-workers (2002). The purified virus was biotinylated and allowed to react
with a bispecific protein, a fusion between the FGF (or EGF) and avidin. The modified virus
was able to alter the tropism of AAV to target EGF and FGFR expressing cells and successfully
lead to transduction [Ponnazhagan, S et al., 2002].
2.3. Mosaic Capsid – Capsid subunits from Different Serotypes are Assembled into a Single
Virion
A mosaic capsid AAV is a virion that is composed of a mixture of viral capsid proteins from
different serotypes. The capsid proteins are provided by complementation with separate
plasmids, which were mixed at a various ratios. During viral assembly, the different serotypes
capsid proteins are theoretically mixed in each virion, at subunit ratios stoichiometrically
reflecting the ratios of the complementing plasmids. Two studies were performed using this
approach by Xiao et al. and Rabinowitz et al. In an effort to combine the muscle tropism of
AAV1 [Xiao, W et al., 1999] and the HSPG binding ability of AAV2 [Summerford, C and
Samulski, RJ, 1998], mosaic virus was generated out of a mixture of AAV1 and 2 capsid
components [Hauck, B et al., 2003]. The mosaic virus, composed of, theoretically, 50% of
viral capsids from each parental serotype, can bind to heparin for purification, and has superb
transducing efficiency in both muscle and liver cells in vivo. Even though the actual ratio of
viral capsid contributed from each serotype cannot be directly determined, the result strongly
suggested that the mosaic virus is a promising approach to generate more sophisticated viruses
with properties of both parental serotypes.
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Apart from combining the advantages of parental serotypes, the unexpected gain of function
of mosaic virus vectors can also provide counter-intuitive insights in understanding both
functionality and biological significance of various capsids. A more comprehensive study was
performed to produce mosaic viruses from 5 parental serotypes (AAV1 to 5) with 5 different
ratios (1:19, 1:3, 1:1, 3:1, 19:1) of input plasmids encoding different serotype capsid sequences
[Rabinowitz, JE et al., 2004]. The results demonstrated that the AAV1 to 3 serotypes are more
compatible to each other in terms of co-assembly into capsids, while AAV5 capsids
components are less compatible with these three serotypes. Likewise, a transfection containing
only 5% plasmids expressing AAV4 capsid, in a mixture of plasmids expressing AAV1, 2, or
3, capsids resulted in inhibition of viral assembly. The mixture of AAV3 and AAV5 at a 3:1
ratio produced a mosaic virus that exhibited both heparin and mucin binding ability,
demonstrating that the virus carries properties from both parental serotypes. In addition, even
though AAV1 and AAV2 alone do not transduce C2C12 cells efficiently, mosaic virus
AAV1/2, with only 5% of input expressing AAV1 capsid mixed with that expressing AAV2
capsids, displays dramatically increased transduction efficiency on C2C12 cells when
compared to the two parental wt serotypes. Further studies suggested that AAV1 could be
trafficked differently than AAV2, which suggested that the AAV1 and 2 mosaic virus described
above could be trafficked in a different route than AAV2, and more efficiently deliver the
genome to the nucleus for transduction. The series of mosaic virus generated in this study are
important tools for us to further understand the biology of different AAV serotype capsids and
warrant revisiting in an in vivo setting.
2.4. Chimeric Capsids
Chimeric capsid AAV can be defined as an insertion of a foreign protein sequence, either from
another wt AAV sequence or an unrelated protein, into the open reading frame of the capsid
gene. Among all the methods and strategies used in generating chimeric capsid sequences,
most studies performed can be categorized into four groups:
2.4.1. Using naturally existing serotypes as templates;
2.4.2. Using an epitope coding sequence fused to the N- or C-terminus of the capsid coding
sequence;
2.4.3. Using an epitope sequence inserted into a specific position in the capsid coding sequence;
2.4.4. Using an epitope identified from a peptide library to inserted into a specific position in
the capsid coding sequence.
2.4.1. Chimeric Capsid 1 – Chimeric Capsid Proteins Generated by
Recombination between Two (or more) Naturally Occurring AAV Serotypes
Capsid Sequences—A marker rescue approach was applied to generate chimeric capsid
sequences. Three AAV2 capsid mutant sequences that had been previously characterized as
non-infectious and unable to bind to heparin were rescued after co-transfection of the coding
sequences with wt AAV3 capsid DNA sequence [Bowles, DE et al., 2003]. Microhomology
between the mutant AAV2 and wt AAV3 capsid coding sequences served as crossover points
for homologous recombination initiated by cellular proteins. The recombined sequences
encoded functional chimeric proteins due to directed selection, leading to the production of
infectious vectors that could bind to heparin sulfate. This method could serve as a tool to
generate a large number of chimeric viruses with unique properties depending on the criteria
set in the screening process.
2.4.2. Chimeric Capsid 2 – Epitope Tagged at N- or C-terminus of Capsid
Proteins—The structure of the viral capsid and the viral genes carried within has evolved for
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millions of years to naturally select for stable and efficient variants for survival. Alignment of
the viral capsid gene among all naturally occurring serotypes demonstrated that some
conserved domains exist for structural stability of the AAV capsid. To alter the natural tropism
of the virus for cell-type retargeting is challenging, especially if a foreign epitope is to be
inserted into the capsid sequence.
The important parameters for epitope tagging onto AAV capsids are as follows:
A. The Site of Insertion of the Epitope Must be Such That
i. assembly of the viral capsid, internalization, trafficking and nuclear import
are not affected; and
ii. peptides must be exposed on the surface of the virus;
B. The Choice of Retargeting Peptide Requires
i. high affinity binding of the targeting receptor/binding site of interest; and
ii. high specificity to increase efficacy, especially if the virus is to be
administered via a systemic route for clinical studies.
Several groups performed insertional or mutational studies to generate infectious virus that
carries an epitope tag to alter tissue tropism. In order to generate a new AAV that infects
hematopoietic stem/progenitor cells with higher efficiency, Yang and co-workers (1998)
utilized the single-chain variable region (sFv) of an anti-CD34 antibody and fused it to the N-
terminus of each of the three AAV2 capsid genes [Yang, Q et al., 1998]. While the N-terminal
tag on each of the three capsid proteins did not yield infectious virus, a mosaic virus assembled
from a mixture of the three wt capsid proteins and the N-terminal tagged sFv-VP2 capsid, can
generate virus that gives improved infection efficiency of CD34 expressing cell line, KG-1.
This was the first study that claimed to report successful generation of infectious and functional
virus with a foreign peptide fused to the N-terminus of VP2 of AAV2. However, these results
have not been reproduced, and it is clear that the ability to form viral like particles that are not
assembled properly is a common phenomena. The lack of physical characterization of these
proposed chimeric capsid proteins and the virion structure left the field wanting to believe the
possibility, but lacking the rigor and proof to confirm that chimeric AAV capsid proteins would
be a ready substrate for molecular tinkering. However, these were early days and many of the
techniques commonly used were not developed and lack of ability to reproduce the report left
this primary example lacking for supporters.
In a separate study, the influenza virus hemagglutinin (HA) tag (YPYDVPDYA) was inserted
at the N-terminus of each of the three capsid genes and at the C-terminus of the capsid open
reading frame, which is shared by all three proteins [Wu, P et al., 2000]. The results showed
that peptide insertion could be tolerated at the N-terminus of VP1 (amino acid 1 in the cap
ORF), the N-terminus of VP2, which is also the amino acid 138 of VP1 (amino acid 138 in the
cap ORF) but not at the N- terminus of VP3 or the shared C-terminus. In addition, AAV with
serpin receptor ligand peptide (KFNKPFVFLI) fused to the N-terminus of VP1 or VP2 can
increase infection efficiency in IB3 cells. Similarly, insertion of a ligand derived from
apolipoprotein E (ApoE) at position 138, generated infectious vector with a higher transduction
efficiency than wt AAV2 for low-density lipoprotein receptor (LDL-R) expressing human
islets cells [Loiler, SA et al., 2003]. Furthermore, Warrington et al. (2004) determined the best
position for terminal epitope tagging to generate near wt titer and infectivity to be the N-
terminus of VP2 in the presence of unaltered sequences of VP1 and VP3 [Warrington, K.H,
Jr. et al., 2004], The infectivity of the epitope tagged viruses expressing an 8 kDa chemokine
binding domain of rat fractalkine (FKN) or 18 kDa human hormone leptin (LEP) at this position
showed no significant difference in viral properties when compared to wt virus, except the gain
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of ability for the tagged virus to target the corresponding cellular receptors. It has also been
shown that the addition of a 30 kDa GFP tag at the N-terminus of VP2 (with wt sequences of
VP1 and VP3) can yield a virus only 3 fold less infectious than wt, further suggesting that VP2
is non-essential for AAV infectivity. In a different study, Zhang et al (2002) described a
chimeric AAV, composed of wt AAV VP1 and 2 proteins, and a C-terminal 6-His-tagged VP3,
which yielded infectious and wt-like virus that can be readily purified by using a Ni-
nitrilotriacetic acid column [Zhang, HG et al., 2002]. Nevertheless, the VP2 N-terminus is by
far the best terminal position for epitope tagging for AAV capsid protein.
2.4.3. Chimeric Capsid 3 – Epitope Tagged in the ORF of the Capsid Proteins—
The position chosen for epitope insertion is very critical for maintaining the efficiency of viral
infection, in terms of assembly, DNA packaging, and trafficking, with an increased efficacy
in transducing the desired target cells. The VP2 N-terminal epitope tag strategy described in
the previous section is useful for generating infectious virus with additional tropism. However,
the disadvantage of this approach is that the HSPG binding ability (in the case of AAV2) was
not completely abolished. While this property can be useful for vector purification, it also
mediates infection of a very broad range of cell types. This may lead to transgene expression
in cell-types where it could be deleterious, or simply to dilution of the vector dose in tissues
where it is not useful. It would therefore be advantageous in some therapeutic applications to
mutate the HSPG binding amino acids to abrogate binding and deter the natural cell tropism.
Before the availability of the x-ray crystallographic structure, many mutational and epitope
tagging studies contributed significantly to identifying positions that are on the surface of the
viral capsid. These studies also pointed to regions of the capsid which might be involved in
HSPG binding and are summarized as follows.
One of the first studies on AAV capsid mutagenesis was performed using small peptide
insertional mutagenesis randomly in the AAV2 capsid gene and screening for positions that
can tolerate insertions without the loss of function [Rabinowitz, JE et al, 1999]. Eighteen
mutants were generated, ranging from the phenotype completely incapable of assembling
virions, to those which generate vector liters similar to wt virus. In particular, one mutant that
is only composed of VP3 (H2634) can assemble into an intact virus that binds to HSPG but
fails to transduce cells. This suggests that VP1 and/or VP2, despite being minor contributors
to the viral capsid composition, are responsible for viral infectivity, and VP3 is responsible for
HSPG binding and structural support of the virus.
In another study, a 14-amino-acid peptide L14 (QAGTFALRGDNPQG), containing an RGD
sequence, was inserted into specific positions in the AAV2 capsid gene for retargeting AAV2
to infect cells displaying αvβ5 integrin, but are otherwise non-permissive to wt AAV2 [Girod.
A et al., 1999]. Taking advantage of the crystal structure solved for Canine parvovirus [Tsao,
J et al., 1991], Girod et al. built a hypothetical model by sequence alignment between the AAV2
VP3 and canine parvovirus VP2 proteins. Based on this alignment, six positions on the AAV2
VP3 capsid protein were proposed for epitope insertion that potentially would not disturb the
viral life cycle (1–261, 1–381, 1–447, 1–534, 1–573 and 1–587), In particular, insertion at 1–
587 altered the viral tropism to gain specificity in binding to integrin and significantly dampen
the wt AAV2 HSPG binding ability. A few years after this study, residues R-585 and R-588.
which were neighboring sites of 1–587, were demonstrated to be responsible for HSPG binding
[Opie, SR et al., 2003].
As mentioned in the previous section, Wu et al. (2000) performed a comprehensive
mutagenesis study on the AAV2 capsid before the availability of the crystal structure. Other
than placing insertions at the terminus of the capsid proteins, the authors tested a total of 93
mutants at 59 different positions for the acceptance of foreign peptide insertion. Among all
tested sites, only insertion at residue 138 in the VP1 sequence, which is also the N-terminus
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of VP2, yielded a virus with reduced infectivity, but still acceptable for practical use. In other
studies, similar capsid positions were tested for cell-type retargeting using an epitope that is a
ligand of human luteinizing hormone receptor (LH-R) [Shi, W et al., 2001]. These
modifications at residues 139 (N-terminus) and 161 in VP2 sequence and residues 459, 584
and 587 in VP3 sequence, are able to retarget AAV2 to LH-R expressing OVCAR-3 cells.
Even with 15 amino-acid peptide insertion, the viruses were able to display the epitope on their
surfaces and yield titers similar to wt. Further experiments demonstrated that the insertion at
residue R588 can inhibit AAV2 from binding to HSPG [Shi, W and Bartlett. JS, 2003]. The
strategy of VP2 N-terminus insertion was further confirmed by Warrington et al.’s study
(2004), in which the viral production and infectivity could be rescued if the insertion was
exclusively at the N-terminus of VP2 (as discussed above). Also, other studies have shown
that an insertion at residue 587 can disrupt the interaction of AAV2 to primary receptor HSPG,
and allow retargeting of the virus to bind to the receptor of interest [Nicklin, SA et al., 2001].
2.4.4. Chimeric Capsid 4 – Using a Library Approach in to Screen for Useful
Ligand Specific Epitopes—The previous sections on chimeric capsids describe an
insertion of a known peptide sequence as a ligand to a receptor expressed on the target cell
type. The search for a position that can tolerate peptide insertion for receptor retargeting and
yet be able to retain most of the biological properties of AAV was difficult and tedious. After
all, even a slight alteration in viral capsid structure could affect receptor binding and potentially
downstream events, thus reducing transduction efficiency. Three recent studies used a library,
or a directed evolution, approach to generate new chimeric capsid AAV for a more versatile
retargeting vector. Muller et al. (2003) employed a random 7-residue peptide library inserted
next to the R588 position of AAV2 capsid sequence to ensure that the peptide is displayed on
the virus surface and, at the same time, to ablate the HSPG binding ability. The AAV library
was then screened for the ability to infect human coronary artery endothelial cells, and the
sequences from infectious virus were cloned for analysis. A chimeric capsid AAV carrying the
peptide sequence NDVRAVS was shown to efficiently infect coronary cells in vitro, while one
with peptide sequence NSSRDLG was efficient for infection of the mouse heart after tail vein
injection in vivo [Muller, OJ et al., 2003]. The same approach of 7-amino-acid random peptide
insertion into the same capsid domain was performed by Perabo et al. [Perabo, L et al.,
2003]. More recently, a study demonstrated the feasibility of a “staggered extensive process”,
analogous to DNA shuffling [Maheshri, N and Schaffer, DV, 2003], to develop a method to
generate interesting viral capsid mutants (Maheshri N. et al, personal communication).
Maheshri et al. used this DNA shuffling approach to generate rAAV2-based capsids that evade
neutralizing antibodies and also have reduced heparin binding ability. These studies could
potentially he extended to select chimeric capsid AAV for hybrid AAV for in vivo systemic
delivery with high efficiency and efficacy.
In conclusion, the development of chimeric hybrid serotypes, with epitope tags up to 30kDa
at the N-terminus of VP2, is the ideal position for insertion if the HSPG binding ability is
required to be maintained, while amino acid position 1–587 is the best position for epitope
insertion if an alteration of tropism is mandatory for the hybrid virus.
3. IMPLICATIONS FOR USE OF AAV HYBRID SEROTYPES
Long term gene expression and varied tissue tropism from different serotypes of AAV had
been demonstrated previously. However, more specific modification on the viral capsids is
required to further expand the use of AAV as a gene delivery vector. For instance,
transcapsidation of the AAV2 genome into other serotype capsids allows the genome from a
well characterized serotype to gain the ability to infect cells that are more susceptible to other
serotypes [Rabinowitz, JE et al., 2002]. Other than transcapsidation. capsid modification with
an epitope tag can greatly expand the use of AAV in many different target cell types or disease
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models, A small suicide protein can be fused to the N-terminus of VP2, with an enzymatic
cleavage sequence that could be processed by a common host cell enzyme and used for
delivering the toxic peptide to cancer cells. In addition, the attachment of a receptor-specific
ligand to the viral surface can further increase the specificity of the virus in infecting cells/
tissues of interest. Multiple epitope labeling of AAV can potentially facilitate binding to
specific primary and secondary receptors, causing the virus to be efficiently bound and
internalized for transduction.
Other than for therapeutic uses, AAV hybrid serotypes greatly enhance our understanding of
the virus biology. In the course of generating hybrid serotypes by a variety of methods, large
scale mutagenesis studies were performed. Many of these mutants, ranging from single residue
mutation to up to 30 kDa peptide insertions as an epitope tag, shed light on the residue or the
region(s) of the capsid that is/are responsible for virion packaging, genome import, attachment
of cellular surface receptor, internalization, trafficking, endosornal escape and nuclear
localization. These results would provide enormous valuable knowledge for AAV basic
virology.
3.1. Receptor Targeting to Specific Cell Types and Viral Assembly
Mosaic viruses produced by mixing the plasmids that express AAV3 and 5 capsids generated
hybrid serotypes that gain properties from both parental serotypes in binding to HSPG and
mucin [Rabinowitz, JE et al., 2004]. Using the same strategy, mosaic virus can be used to
screen for efficient binding to primary and secondary receptor of the target cells to improve
the infection efficiency of wt virus. In addition, this study described a new method to classify
AAV serotypes into subgroups according to the compatibility of the subunits of one serotype
to the other serotypes. The results indicated that AAV 1–3 capsids (subgroup A, as classified
by Rabinowitz et al.,) are more compatible to each other, with moderate compatibility to mix
with AAV5 capsids (subgroup B). However, AAV4 capsids (subgroup C) do not mix well with
AAV1–3 capsids. Similar studies to be performed on other available AAV serotypes would
provide us with a better understanding of the different properties of these serotypes, so that
hybrid vectors with multiple desired properties from each parental serotype can be generated.
Viral assembly can also be studied with hybrid serotypes. Mutants generated in capsid mutation
studies can be used to identify important domains of the capsid that are critical for viral
assembly. For example, Wu et al. (2000) demonstrated that alanine substitution at specific
capsid positions carrying charged amino acids generated mutant viruses that were not able to
assemble (amino acids 228–232, 235–239, 285–289, 291–295, 307–311, 607–611, 681–683,
689–693). These mutants could be further analyzed in silico and in vitro to determine the amino
acids that contribute to the interactions among viral capsid subunits and assembly kinetics of
the capsid. In addition, a mutation at R-432 to A-432 alone can generate empty capsid. Further
analyses of this mutant would explain the DNA packaging deficiencies that lead to formation
of empty capsid, and potentially provide details in the mechanism of genome packaging.
Moreover, the function of individual viral proteins (VP1, 2 and 3) of different serotypes
(AAV1-11 and/or hybrid serotypes capsids) can be studied by mixing plasmids that express
specific VP proteins (e.g. VP1) from one serotype and other VP proteins (e.g. VP2 and 3) from
a different serotype. The regions of the proteins that contribute to the specific properties of the
wt and/or modified virus can allow us to understand the various functions of each capsid
protein.
3.2. Signal Transduction
A microarray study of gene expression profiles following infection with AAV2 or an empty
AAV capsid showed that cell proliferation proteins were down-regulated and p21 was up-
regulated in infected cells. The authors further demonstrated that the AAV2 capsid is
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responsible for initiating the G2/M delay [Stilwell, JL and Samulski, RJ, 2004]. It is possible
that the capsid binding to its receptor can trigger such a response through a signal transduction
cascade from the receptor to the nucleus during the initial step of viral infection. The swap of
a domain of AAV2 capsid with that of AAV3 capsid, which does not cause the G2/M delay,
reduced the delay observed with wt AAV2 capsid, highlighting the important role of HSPG
binding in triggering signaling events that caused cell cycle delay (Stilwell JL, unpublished
data). In another study, Rac1 and PI3 kinase cascade activation was demonstrated to be a result
of AAV2 endocytosis mediated by the αvβ5 integrin internalization pathway [Sanlioglu, S et
al., 2000]. The domain on the viral capsid responsible for assisting the interaction between the
virus and integrin is unknown, but can be mapped out using similar strategies used in
identifying the capsid binding domain for HSPG.
3.3. AAV Trafficking
Hybrid serotypes can also be used to study AAV trafficking. Investigations on AAV receptor
binding, which is the first step of AAV infection, allow us to identify a variety of cell surface
receptors that are utilized by AAV (HSPG, αvβ5 integrin, FGFR-1 and HGF). The subsequent
step in the infection process involves clathrin-dependent and independent internalization. It
has been shown that AAV must be transported from early to late endosomal compartments,
followed by an escape from the endosome to reach the nucleus [Douar, AM et al., 2001].
Researchers have demonstrated that the lack of AAV transduction in certain cell types (eg.
differentiated human airway epithelial cells} was due to inefficient endosomal processing and
nuclear trafficking [Duan, D et al., 2000]. In addition, a separate study using NIH3T3 cells
showed that the endosomal pathway of this cell line is functional, but the endosomal processing
from early to late endosome is impaired such that AAV is not trafficked to the nucleus [Hansen,
J et al., 2001]. Proteasome inhibitors such as MG-132 and LLnL can increase the number of
virus transported to the nucleus and eventually leading to transduction [Duan, D et al., 2000;
Douar, AM et al., 2001]. Therefore, mutation studies on the capsid that lead to altered
endosomal trafficking and/or processing can help us to identify the essential regions of the
capsid that mediate this process, and help to identify the host components that they interact
with. Moreover, AAV virion and capsid proteins are ubiquitinated after endocytosis [Yan, Z
et al., 2002]. However, the target residue(s) and/or domain(s) on the capsid to be ubiquitinated
are still unclear. Capsid mutational studies and hybrid viruses can direct us to identify the target
sites and allow us to understand the role of AAV capsid ubiquitination in improving AAV
transduction.
In addition, hybrid AAV vectors can be used to study AAV trafficking in a real time manner.
Confocal microscopy was previously used to visualize AAV trafficking through the cytoplasm
using a Cy3-labeled AAV virus [Sanlioglu, S et al., 2000]. Even though the labeled virus is a
useful tool in studying trafficking, a minor drawback of the study is that the conjugated label
can fall off from the virus, leading to the tracking of the dye instead of the virus. Warrington
et al. (2004) described a VP2-N-terminal GFP-tagged virus to perform real-time imaging to
study viral trafficking [Sanlioglu, S et al., 2000; Warrington, KH, Jr. et al., 2004]. This is an
improved tool for trafficking study because the fluorochrome is covalently attached to the viral
capsid sequence.
4. IMPORTANT CONSIDERATIONS WHEN USING HYBRID SEROTYPES
Despite the fact that hybrid serotypes have enormous potential in therapeutic applications and
in solving a wide spectrum of questions in AAV biology, researchers and clinicians should be
cautious when using hybrid serotype for their studies. First, there is no universal cell line in
testing the transduction efficiency of all serotypes. For example, AAV1 (a naturally isolated
serotype) transduces muscle tissue very well [Xiao, W et al., 1999] but is not very efficient in
transduction in vitro, including C2C12 cells (a muscle cell line) [Rabinowitz, JE et al., 2004].
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Therefore, screening new mutants using cell lines alone may lead to false negatives, because
mutants that work extremely well in vivo could be neglected. However, animal experiments
are often expensive and time consuming for screening purposes. Second, normalizing the
infectious doses of vectors among different serotypes in comparative studies, based on their
ability to infect a standard cell type such as HeLa, can be misleading. Because each serotype
has different transduction efficiency for a particular cell-type, infectious titers derived in this
way are not directly comparable. In this case, quantification of genome containing particles by
dot blots and/or quantitative PCR (QPCR) becomes more important. A standardized protocol
for virus quantification and a widely available viral stock to serve as a reference should be used
across the field to provide a better comparison among results obtained in different laboratories.
However, this does not allow the investigator to evaluate the viability of new vector stocks.
Third, the screening process for identifying a desired hybrid serotype should meet stringent
criteria in efficiency, efficacy, purity and safety. For serotypes to be tested in a clinical setting,
the viruses should allow efficient delivery to the target cells and specifically to the tissue of
interest. Since post modification (e.g. antibody adsorption on the surface of the virus) or mixing
of reagents (e.g. plasmids expressing different AAV serotype capsids in mosaic virus) are used
in generating the virus, potential unforeseen interactions and/or properties can result. Quality
control of the output virus needs to be carefully and vigorously tested and validated.
5. FUTURE DIRECTIONS: WHERE DO WE GO FROM HERE?
This review has focused on the use of hybrid serotypes as one of the strategies for improving
viral genome delivery. However, to further improve AAV as a gene delivery vector,
modifications of the viral genome is as important as capsid modifications, in order to achieve
an exceptional level of transduction. Second-strand synthesis has been identified as a rate-
limiting step in rAAV vector transduction in many tissue cell types [McCarty, DM et al.,
2001]. Self-complementary AAV (scAAV) has been one of the most important advances in
AAV vector development. By deleting the trs from one of the ITRs, the Rep protein continues
to replicate along the genome using the coding sequence as a template, thus generating a single-
stranded genome that contains both the coding and the complementary sequence packaged into
the viral capsid [McCarty, DM et al., 2003]. After the delivery of the genome to the nucleus,
the genome folds from the TR at the mutated end. Since the complementary strand of the
genome is already provided to the host cells, gene expression immediately occurs after the
genome gets into the nucleus. This vector has been demonstrated to be an improved
transduction vector with a fast onset of gene expression. Inspite of the reduction of the
packaging size, scAAV vectors can deliver smaller transgene expression cassette (up to 2.3kb).
Recently, scAAV has been exploited for delivering small-interference RNA (siRNA)
expressing cassette [Tomar, RS et al., 2003; Han, W et al., 2004; Pinkenburg, O et al., 2004;
Xia, H et al., 2004; Zhang, W et al., 2004]. These studies demonstrated that scAAV could
efficiently deliver the siRNA expression cassette and lead to an optimum level of siRNA
silencing. The scAAV genomes can be packaged into the hybrid serotypes and can potentially
lead to an even better and broader expression in the target tissues when compared to the
conventional single-stranded genomes. With this strategy in mind, development of AAV with
mutant capsids that can assemble the virus to package a bigger genome can further expand the
forefront of the use of this vector to carry a larger transgene expression cassette.
Hybrid serotypes of AAV have been shown to have tremendous potential for efficient gene
delivery and for understanding AAV biology in the past. In the future, we can foresee that more
hybrid serotypes will be designed and generated depending on the specific criteria for each
application, thus further broadening the potential use of AAV as a gene delivery vector. With
better knowledge of how to overcome other limiting factors of AAV transduction (e.g.
internalization, endosomal trafficking, nuclear import, etc), researchers can re-examine cell
types or organs that could not be targeted before, or disease models that could not be treated
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using AAV vectors. Further advances in understanding AAV biology can allow researchers to
generate more efficient gene delivery vectors to the benefit of the patients that are in need of
gene therapy.
Acknowledgements
We thank Jackie Stilwell for unpublished information and Josh Grieger and Aravind Asokan for critically reading and
useful discussion of the manuscript. This work was supported in part by NIH grant HL066973 and HL051818 and
NIH grant AI048074 awarded to Dr. Douglas McCarty.
References
Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling SE, Anand V,
Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J. Gene therapy restores vision in a
canine model of childhood blindness. Nat Genet 2001;28:92–5. [PubMed: 11326284]
Agbandje M, McKenna R, Rossmann MG, Strassheim ML, Parrish CR. Structure determination of feline
panleukopenia virus empty particles. Proteins 1993;16:155–71. [PubMed: 8392729]
Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of
dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum
Gene Ther 1996;7:841–50. [PubMed: 8860836]
Amiss TJ, McCarty DM, Skulimowski A, Samulski RJ. Identification and characterization of an adeno-
associated virus integration site in CV-1 cells from the African green monkey. J Virol 2003;77:1904–
15. [PubMed: 12525625]
Asfour B, Baba HA, Scheld HH, Hruban RH, Hammel D, Byrne BJ. Uniform long-term gene expression
using adeno-associated virus (AAV) by ex vivo recirculation in rat-cardiac isografts. Thorac
Cardiovasc Surg 2002;50:347–50. [PubMed: 12457311]
Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science
1965;149:754–6. [PubMed: 14325163]
Auricchio A, Kobinger G, Anand V, Hildinger M, O’Connor E, Maguire AM, Wilson JM, Bennett J.
Exchange of surface proteins impacts on viral vector cellular specificity and transaction characteristics:
the retina as a model. Hum Mol Genet 2001;10:3075–81. [PubMed: 11751689]
Auricchio A, O’Connor E, Hildinger M, Wilson JM. A single-step affinity column for purification of
serotype-5 based adeno-associated viral vectors. Mol Ther 2001;4:372–4. [PubMed: 11592841]
Bantel-Schaal U, Zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated
from a genital site. Virology 1984;134:52–63. [PubMed: 6324476]
Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector
transduction of nonpermissive cells mediated by a bispecific F(ab′ gamma)2 antibody. Nat Biotechnol
1999;17:181–6. [PubMed: 10052356]
Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-
associated virus vectors. J Virol 2000;74:2777–85. [PubMed: 10684294]
Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237–45.
[PubMed: 7748178]
Bossis I, Chiorini JA. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant
AAAV particles. J Virol 2003;77:6799–810. [PubMed: 12768000]
Bowles DE, Rabinowitz JE, Samulski RJ. Marker rescue of adeno-associated virus (AAV) capsid
mutants: a novel approach for chimeric AAV production. J Virol 2003;77:423–32. [PubMed:
12477847]
Chiorini JA, Afione S, Kotin RM. Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique
terminal resolution site compared with other AAV serotypes. J Virol 1999;73:4293–8. [PubMed:
10196327]
Chiorini JA, Kim F, Yang I, Kotin RM. Cloning and characterization of adeno-associated virus type 5.
J Virol 1999;73:1309–19. [PubMed: 9882336]
Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM. Cloning of adeno-associated virus type 4 (AAV4) and
generation of recombinant AAV4 particles. J Virol 1997;71:6823–33. [PubMed: 9261407]
Choi et al. Page 15













Chipman PR, Agbandje-McKenna M, Kajigaya S, Brown KE, Young NS, Baker TS, Rossmann MG.
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its
cellular receptor. Proc Natl Acad Sci USA 1996;93:7502–6. [PubMed: 8755503]
Clarke JK, McFerran JB, McKillop ER, Curran WL. Isolation of an adeno associated virus from sheep.
Brief report. Arch Virol 1979;60:171–6. [PubMed: 226038]
Conway JE, Zolotukhin S, Muzyezka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus
type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon
expressing Rep and Cap. J Virol 1997;71:8780–9. [PubMed: 9343238]
Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N. Adeno-associated virus-me dialed
delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 2000;7:1930–9. [PubMed: 11127581]
Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA.
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and
regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000;97:3428–32.
[PubMed: 10688913]
Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. Identification of
PDGFR as a receptor for AAV-5 transduction. Nat Med 2003;9:1306–12. [PubMed: 14502277]
Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors
routing to the late endosomal compartment and proteasome degradation. J Virol 2001;75:1824–33.
[PubMed: 11160681]
Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-
associated virus type 2 infection. J Virol 1999;73:10371–6. [PubMed: 10559355]
Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized
airway epithelia by adeno-associated virus. J Clin Invest 2000;105:1573–87. [PubMed: 10841516]
Dubielzig R, King JA, Weger S, Kern A, Kleinschmidt JA. Adeno-associated virus type 2 protein
interactions: formation of pre-encapsidation complexes. J Virol 1999;73:8989–98. [PubMed:
10516005]
During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth
RH, Sladek JR Jr, O’Malley KL, Redmond DE Jr. In vivo expression of therapeutic human genes for
dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther
1998;5:820–7. [PubMed: 9747462]
Farkas SL, Zadori Z, Benko M, Essbauer S, Harrach B, Tijssen P. A parvovirus isolated from royal python
(Python regius) is a member of the genus Dependovirus. J Gen Virol 2004;85:555–61. [PubMed:
14993638]
Flotte TR. Recombinant adeno-associated virus vectors for cystic fibrosis gene therapy. Curr Opin Mol
Ther 2001;3:497–502. [PubMed: 11699895]
Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of Adeno-associated
viruses are widely disseminated in human tissues. J Virol 2004;78:6381–8. [PubMed: 15163731]
Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from
rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99:11854–9.
[PubMed: 12192090]
Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deleage G, Hallek M. Genetic capsid
modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999;5:1052–
6. [PubMed: 10470084]
Han W, Wind-Rotolo M, Kirkman RL, Morrow CD. Inhibition of human immunodeficiency virus type
1 replication by siRNA targeted to the highly conserved primer binding site. Virology 2004;330:221–
32. [PubMed: 15527848]
Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. impaired intracellular trafficking of adeno-associated
virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000;74:992–6.
[PubMed: 10623762]
Hansen J, Qing K, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: altered endocytic
processing enhances transduction efficiency in murine fibroblasts. J Virol 2001;75:4080–90.
[PubMed: 11287557]
Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol
Ther 2003;7:419–25. [PubMed: 12668138]
Choi et al. Page 16













Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read
MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of
canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated
viral vector. Nat Med 1999;5:56–63. [PubMed: 9883840]
Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM. Hybrid vectors based on adeno-
associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001;75:6199–203.
[PubMed: 11390622]
Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus
preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA
1966;55:1467–74. [PubMed: 5227666]
Jacobson ER, Kopit W, Kennedy FA, Funk RS. Coinfection of a bearded dragon, Pogona vitticeps, with
adenovirus- and dependovirus-like viruses. Vet Pathol 1996;33:343–6. [PubMed: 8740710]
Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4)
and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ
in sialic acid linkage specificity. J Virol 2001;75:6884–93. [PubMed: 11435568]
Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5
using ion-exchange chromatography. Hum Gene Ther 2002;13:1235–43. [PubMed: 12133276]
Kaludov N, Padron E, Govindasamy L, McKenna R, Chiorini JA, Agbandje-McKenna M. Production,
purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 4.
Virology 2003;306:1–6. [PubMed: 12620791]
Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai V, Shimada T, Matsumoto K, Nakamura T, Watanabe
M, Oshimi K, Daida H. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus
type 2 infection. J Virol 2005;79:609–14. [PubMed: 15596854]
Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc Natl Acad Sci
USA 2004;101:11628–33. [PubMed: 15289612]
Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human
immunodeficiency virus. J Virol 1994;68:510–6. [PubMed: 8254763]
Li J, Wang D, Qian S, Chen Z, Zhu T, Xiao X. Efficient and long-term intracardiac gene transfer in delta-
sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 2003;10:1807–13.
[PubMed: 12960970]
Llamas-Saiz AL. Structure determination of minute virus of mice. Acta Crystallogr D Biol Crystallogr
1997;53:93–102. [PubMed: 15299974]
Loiler SA, Conlon TJ, Song S, Tang Q, Warrington KH, Agarwal A, Kapturczak M, Li C, Ricordi C,
Atkinson MA, Muzyezka N, Flotte TR. Targeting recombinant adeno-associated virus vectors to
enhance gene transfer to pancreatic islets and liver. Gene Ther 2003;10:1551–8. [PubMed: 12907946]
Maheshri N, Schaffer DV. Computational and experimental analysis of DNA shuffling. Proc Natl Acad
Sci USA 2003;100:3071–6. [PubMed: 12626764]
McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal
repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to
transduction in vivo. Gene Ther 2003;10:2112–8. [PubMed: 14625565]
McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus
(scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther
2001;8:1248–54. [PubMed: 11509958]
McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of
CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996;713:99–107.
[PubMed: 8724980]
Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct
intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model
of hemophilia. Gene Ther 1998;5:40–9. [PubMed: 9536263]
Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno-associated viruses from cynomolgus monkey:
pseudotyping characterization of capsid protein. Virology 2004;330:375–83. [PubMed: 15567432]
Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Klein-schmidt JA, Trepel M. Random peptide
libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat
Biotechnol 2003;21:1040–6. [PubMed: 12897791]
Choi et al. Page 17













Muramatsu S, Mizukami H, Young NS, Brown KE. Nucleotide sequencing and generation of an
infectious clone of adeno-associated virus 3. Virology 1996;221:208–17. [PubMed: 8661429]
Muzyezka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr
Top Microbiol Immunol 1992;158:97–129. [PubMed: 1316261]
Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M,
Baker AH. Efficient and selective AAV2-mediated gene transfer directed to human vascular
endothelial cells. Mol Ther 2001;4:174–81. [PubMed: 11545607]
Olson EJ, Haskell SR, Frank RK, Lehmkuhl HD, Hobbs LA, Warg JV, Landgraf JG, Wunschmann A.
Isolation of an adenovirus and an adeno-associated virus from goat kids with enteritis. J Vet Diagn
Invest 2004;16:461–4. [PubMed: 15460334]
Opie SR, Warrington KH Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino
acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate
proteoglycan binding. J Virol 2003;77:6995–7006. [PubMed: 12768018]
Parks WP, Melnick JL, Rongey R, Mayor HD. Physical assay and growth cycle studies of a defective
adeno-satellite virus. J Virol 1967;1:171–80. [PubMed: 4990036]
Perabo L, Buning H, Kofler DM, Ried MU, Girod A, Wendtner CM, Enssle J, Hallek M. In. vitro selection
of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003;8:151–7.
[PubMed: 12842438]
Pinkenburg O, Platz J, Beisswenger C, Vogelmeier C, Bals R. Inhibition of NF-kappaB mediated
inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods
2004;110:119–22. [PubMed: 15234817]
Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M Jr. Conjugate-based targeting of
recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol
2002;76:12900–7. [PubMed: 12438615]
Ponnazhagan S, Wang XS, Woody MJ, Luo F, Kang LY, Nallari ML, Munshi NC, Zhou SZ, Srivastava
A. Differential expression in human cells from the p6 promoter of human parvovirus B19 following
plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human
megakaryocytic leukaemia cells are non-permissive for AAV in infection. J Gen Virol 1996;77(Pt
6):1111–22. [PubMed: 8683195]
Qing K, Khuntirat B, Mah C, Kube DM, Wang XS, Ponnazhagan S, Zhou S, Dwarki VJ, Yoder MC,
Srivastava A. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine
phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression
in human cells in. vitro and murine tissues in. vivo. J Virol 1998;72:1593–9. [PubMed: 9445062]
Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1
is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999;5:71–7. [PubMed: 9883842]
Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SG, Samulski RJ. Cross-dressing the
virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J
Virol 2004;78:4421–32. [PubMed: 15078923]
Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single
adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables
transduction with broad specificity. J Virol 2002;76:791–801. [PubMed: 11752169]
Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of
recombinant virus. Virology 1999;265:274–85. [PubMed: 10600599]
Rose JA, Maizel JV Jr, Inman JK, Shatkin AJ. Structural proteins of adenovirus-associated viruses. J
Virol 1971;8:766–70. [PubMed: 5132697]
Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated
virus (AAV) serotypes other than AAV type 2. J Virol 1998;72:309–19. [PubMed: 9420229]
Samulski RJ, Berns KI, Tan M, Muzyezka N. Cloning of adeno-associated virus into pBR322: rescue of
intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982;79:2077–
81. [PubMed: 6281795]
Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear
trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase
activation. J Virol 2000;74:9184–96. [PubMed: 10982365]
Choi et al. Page 18













Schmidt M, Katano H, Bossis I, Chiorini JA. Cloning and characterization of a bovine adeno-associated
virus. J Virol 2004;78:6509–16. [PubMed: 15163744]
Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2)
capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene
Ther 2001;12:1697–711. [PubMed: 11560765]
Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors
with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003;7:515–25. [PubMed:
12727115]
Simpson AA, Chipman PR, Baker TS, Tijssen P, Rossmann MG. The structure of an insect parvovirus
(Galleria mellonella densovirus) at 3.7 A resolution. Structure 1998;6:1355–67. [PubMed: 9817847]
Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR,
Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA. Correction of hemophilia B in canine
and murine models using recombinant adeno-associated viral vectors. Nat Med 19;5:64–70.
[PubMed: 9883841]
Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR. Stable therapeutic serum levels of human
alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV)
vectors. Gene Ther 2001;8:1299–306. [PubMed: 11571566]
Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyezka N, Byrne BJ, Atkinson
M, Flotte TR. Sustained secretion of human alpha-I-antitrypsin from murine muscle transduced with
adeno-associated virus vectors. Proc Natl Acad Sci USA 1998;95:14384–8. [PubMed: 9826709]
Stilwell JL, Samulski RJ. Role of viral vectors and virion shells in cellular gene expression. Mol Ther
2004;9:337–46. [PubMed: 15006600]
Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus
type 2 infection. Nat Med 1999;5:78–82. [PubMed: 9883843]
Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-
associated virus type 2 virions. J Virol 1998;72:1438–45. [PubMed: 9445046]
Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating
clinical-grade reagents. Nat Med 1999;5:587–8. [PubMed: 10229239]
Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering
RNA. Oncogene 2003;22:5712–5. [PubMed: 12944921]
Tsao J, Chapman MS, Agbandje M, Keller W, Smith K, Wu H, Luo M, Smith TJ, Rossmann MG,
Compans RW, et al. The three-dimensional structure of canine parvovirus and its functional
implications. Science 1991;251:1456–64. [PubMed: 2006420]
Walters RW, Agbandje-McKenna M, Bowman VD, Moninger TO, Olson NH, Seiler M, Chiorini JA,
Baker TS, Zabner J. Structure of adeno-associated virus serotype 5. J Virol 2004;78:3361–71.
[PubMed: 15016858]
Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J. Binding of adeno-
associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem
2001;276:20610–6. [PubMed: 11262413]
Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated
virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N
terminus. J Virol 2004;78:6595–609. [PubMed: 15163751]
Weitzman MD, Fisher KJ, Wilson JM. Recruitment of wild-type and recombinant adeno-associated virus
into adenovirus replication centers. J Virol 1996;70:1845–54. [PubMed: 8627709]
Wistuba A, Weger S, Kem A, Kleinschmidt JA. Intermediates of adeno-associated virus type 2 assembly:
identification of soluble complexes containing Rep and Cap proteins. J Virol 1995;69:5311–9.
[PubMed: 7636974]
Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. Mutational
analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors
with altered tropism. J Virol 2000;74:8635–47. [PubMed: 10954565]
Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson
BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar
ataxia. Nat Med 2004;10:816–20. [PubMed: 15235598]
Choi et al. Page 19













Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-
associated virus type 1. J Virol 1999;73:3994–4003. [PubMed: 10196295]
Xiao W, Warrington KH Jr, Hearing P, Hughes J, Muzyczka N. Adenovirus-facilitated nuclear
translocation of adeno-associated virus type 2. J Virol 2002;76:11505–17. [PubMed: 12388712]
Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent
mice by adeno-associated virus vector. J Virol 1996;70:8098–108. [PubMed: 8892935]
Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS. The atomic structure of adeno-
associated virus (AAV-2). a vector for human gene therapy. Proc Natl Acad Set USA
2002;99:10405–10.
Xie Q, Hare J, Turnigan J, Chapman MS. Large-scale production, purification and crystallization of wild-
type adeno-associated virus-2. J Virol Methods 2004;122:17–27. [PubMed: 15488616]
Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-
associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant
vectors. J Virol 2002;76:2043–53. [PubMed: 11836382]
Yang Q, Mamounas M, Yu G, Kennedy S, Leaker B, Merson J, Wong-Steal F, Yu M, Barber JR.
Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for
gene therapy. Hum Gene Ther 1998;9:1929–37. [PubMed: 9741431]
Ye X, Rivera VM, Zoltick P, Cerasoli P Jr, Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM.
Regulated delivery of therapeutic proteins after in. vivo somatic cell gene transfer. Science
1999;283:88–91. [PubMed: 9872748]
Zhang HG, Xie J, Dmitriev I, Kashentseva E, Curiel DT, Hsu HC, Mountz JD. Addition of six-His-lagged
peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production.
J Virol 2002;76:12023–31. [PubMed: 12414944]
Zhang W, Singam R, Hellermann G, Kong X, Juan HS, Lockey RF, Wu SJ, Porter K, Mohapatra SS.
Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. Genet
Vaccines Ther 2004;2:8. [PubMed: 15301687]
Choi et al. Page 20
Curr Gene Ther. Author manuscript; available in PMC 2006 May 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
